Severity assessment in asthma: An evolving concept

Slides:

Advertisements

Similar presentations

Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.

Advertisements

D-dimer: A biomarker for antihistamine-resistant chronic urticaria

Mark S. La Shell, MD, Christopher W. Calabria, MD, James M. Quinn, MD

Peter Vadas, MD, PhD, Boris Perelman, PhD, Gary Liss, MD, MS

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

What drives prescription patterns in pediatric asthma management?

Allergen immunotherapy: A practice parameter third update

Pharmacologic rationale for treating allergic and nonallergic rhinitis

Fatty acids, inflammation, and asthma

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD

Atopic dermatitis: Age and race do matter!

Dennis K. Ledford, MD, Sally Wenzel, MD

Applying epidemiologic concepts of primary, secondary, and tertiary prevention to the elimination of racial disparities in asthma Christine L.M. Joseph,

Is 9 more than 2 also in allergic airway inflammation?

Desensitization to Chemotherapeutic Agents

Intramuscular Versus Intravenous Immunoglobulin Replacement Therapy and Measurement of Immunoglobulin Levels During Immunoglobulin Replacement Therapy

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

Fatty acids, inflammation, and asthma

Practice Notes from the AAAI

An Infant with Atopic Dermatitis and Itching After Ingestion of Milk

Hospitalization rates and prognosis of patients with anaphylactic shock in Denmark from 1995 through 2012 Anni Nørgaard Jeppesen, MD, Christian Fynbo.

NAEPP Expert Panel Report

Rising prevalence of asthma is sex-specific in a US farming population

Advancing asthma care: The glass is only half full!

Keith J. Simons, PhD, Margherita Strolin Benedetti, PhD, F. Estelle R

Lieuwe D. Bos, MSc, PhD, Peter J. Sterk, MD, PhD, Stephen J

Demographic and clinical characteristics of children and adolescents with severe or difficult-to-treat asthma Bradley E. Chipps, MD, Stanley J. Szefler,

Physician needs in health informatics: Just ask the docs

Peter M. Wolfgram, MD, David B. Allen, MD

William J. Calhoun, MD, Tmirah Haselkorn, PhD, Dave P

Jewlya Lynn, PhD, Sophie Oppenheimer, MS, MPH, Lorena Zimmer, MA

Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation Leif Bjermer, MD Journal of Allergy.

News & Notes Journal of Allergy and Clinical Immunology

Phillip Lieberman, MD, David Golden, MD

Key findings and clinical implications from The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study Bradley E.

Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management Scott H. Sicherer, MD, Hugh A. Sampson, MD Journal.

Biosimilars and drug development in allergic and immunologic diseases

The status of US allergy/immunology physicians in the 21st century: A report from the American Academy of Allergy, Asthma & Immunology Workforce Committee

Peter Vadas, MD, PhD, Boris Perelman, PhD, Gary Liss, MD, MS

Claus Bachert, MD, PhD, Cezmi A. Akdis, MD

What is an “eosinophilic phenotype” of asthma?

Cephalosporin Side Chain Cross-reactivity

Medication use in children with asthma in Finland from 1995 to 2006

Granulomatous-lymphocytic Interstitial Lung Disease in a Patient with Common Variable Immunodeficiency Phil Lieberman, MD, John Routes, MD The Journal.

H. William Kelly, PharmD Journal of Allergy and Clinical Immunology

Autophagy: Nobel Prize 2016 and allergy and asthma research

Administration of Intravenous Immunoglobulin to a Patient with Hypogammaglobulinemia and Anti-IgA Antibodies Phillip Lieberman, MD, Rima Rachid, MD

Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment

Advances in the approach to the patient with food allergy

Diagnosis and management of early asthma in preschool-aged children

Mark S. La Shell, MD, Christopher W. Calabria, MD, James M. Quinn, MD

Consistently very poorly controlled asthma, as defined by the impairment domain of the Expert Panel Report 3 guidelines, increases risk for future severe.

Prevention of food allergy: Beyond peanut

Racial differences in biologic predictors of severe asthma: Data from the Severe Asthma Research Program Christy Gamble, DrPHc, MPH, Evelyn Talbott,

News Beyond Our Pages Journal of Allergy and Clinical Immunology

Risk of oral food challenges

Benjamin Chaigne, MD, Hervé Watier, MD, PhD

Cost of near-roadway and regional air pollution–attributable childhood asthma in Los Angeles County Sylvia Brandt, PhD, Laura Perez, PhD, Nino Künzli,

Measles and immunomodulation

Guus A. Westerhof, MD, Elise M. Vollema, MD, Els J

Managing asthma exacerbations in the emergency department: Summary of the National Asthma Education and Prevention Program Expert Panel Report 3 guidelines.

Macrolide antibiotics and asthma treatment

Asthma: The past, future, environment, and costs

Interrupting IL-6–receptor signaling improves atopic dermatitis but associates with bacterial superinfection Alexander A. Navarini, MD, PhD, Lars E.

Environmental factors and eosinophilic esophagitis

Advances in pediatric asthma in 2007

News Beyond Our Pages Journal of Allergy and Clinical Immunology

Natural history of cow’s milk allergy

Susan L. Janson, DNSc, Kelly Wong McGrath, BA, Jack K

Primary prevention of asthma and allergy

Presentation transcript:

Severity assessment in asthma: An evolving concept Mary K. Miller, MS, Charles Johnson, MBChB, Dave P. Miller, MS, Yamo Deniz, MD, Eugene R. Bleecker, MD, Sally E. Wenzel, MD Journal of Allergy and Clinical Immunology Volume 116, Issue 5, Pages 990-995 (November 2005) DOI: 10.1016/j.jaci.2005.08.018 Copyright © 2005 American Academy of Allergy, Asthma and Immunology Terms and Conditions

Fig 1 Percentage of TENOR patients age 6 to 55 years with severe asthma: NAEPP versus physician assessment by health care utilization and medication use (N = 2927). Mild/moderate versus severe by physician only: all P < .001. Mild/moderate versus severe by NAEPP only: all P < .05. Mild/moderate versus severe by both physician and NAEPP: all P < .001. Severe by physician only versus severe by NAEPP only: P value for 3+ long-term controllers and high-dose ICS <.05. Severe by physician only versus severe by both physician and NAEPP: all P < .01, except for 3+ long-term controllers. Severe by NAEPP only versus severe by both physician and NAEPP: all P < .01. ER, Asthma-related emergency room visit. Journal of Allergy and Clinical Immunology 2005 116, 990-995DOI: (10.1016/j.jaci.2005.08.018) Copyright © 2005 American Academy of Allergy, Asthma and Immunology Terms and Conditions

Fig 2 Percentage of TENOR patients age 6 to 55 years with severe asthma: GINA versus physician assessment by health care utilization and medication use (N = 2927). Mild/moderate versus severe by physician only: all P < .05, except high-dose ICS. Mild/moderate versus severe by GINA only: all P < .01. Mild/moderate versus severe by both physician and GINA: all P < .001. Severe by physician only versus severe by GINA only: P value for high-dose ICS < .001. Severe by physician only versus severe by both physician and GINA: all P < .05. Severe by GINA only versus severe by both physician and GINA: all P < .001, except for high-dose ICS. ER, Asthma-related emergency room visit. Journal of Allergy and Clinical Immunology 2005 116, 990-995DOI: (10.1016/j.jaci.2005.08.018) Copyright © 2005 American Academy of Allergy, Asthma and Immunology Terms and Conditions